
Abridge
$188.82
Source:$3.71 (2.00%)past six months
Abridge Valuation
Follow estimated valuations, share price trends, and company updates for Abridge.
About Abridge
Abridge uses artificial intelligence to listen to and interpret spoken medical conversations and automatically turn them into organized clinical documentation that supports healthcare workflows and reduces administrative burden. Its technology focuses on enhancing clarity and efficiency in capturing key information from discussions between patients and clinicians, helping streamline record‑keeping...read more
| Co-Founder | Shivdev Rao |
| Co-Founder | Zack Lipton |
| CEO | Shivdev Rao |
| COO | Julia Chou |
| CFO | Sagar Sanghvi |
| CTO | Zack Lipton |
| Headquarters | Pittsburgh, PA |
| Founded | 2018 |
| Sector | AI & Machine Learning |
Abridge Funding History
| Financing Round | Date | Amount |
|---|---|---|
| Series E | Jun 24, 2025 | $300M |
| Abridge AI Series E | May 30, 2025 | Undisclosed |
| Series D | Feb 17, 2025 | $250M |
| Series C | Feb 22, 2024 | $141M |
| Series B | Oct 26, 2023 | $30M |
| Series A-1 | Aug 11, 2022 | $12M |
Abridge lead investors
- American College of Cardiology
- Andreessen Horowitz
- Aneesh Chopra
- Bessemer Venture Partners
- California Health Care Foundation
- CapitalG
- CVS Health
- Elad Gil
- Esther Dyson
- Individuals
- Institutional Venture Partners
- Kaiser Permanente Ventures
- KdT Ventures
- Khosla Ventures
- K. Ventures
- Lifepoint Health
- Lightspeed Venture Partners
- Mass General Brigham (Artificial Intelligence and Digital Innovation Fund)
- Mayo Clinic
- NVentures
- Pillar Companies
- Redpoint Ventures
- SCAN Group
- Spark Capital
- SV Angel
- UC Investments (UCOP)
- Union Square Ventures
- UPMC Enterprises
- Whistler Capital Partners
- Wittington Ventures
- Yoshua Bengio
FAQ
Frequently asked questions
Abridge's estimated secondary market share price is $188.82 as of April 2026.
Abridge's last official round, Series E, was for $300M.
Abridge's last known funding was on Jun 24, 2025 for $300M.
Abridge's major investors are American College of Cardiology, Andreessen Horowitz, Aneesh Chopra, Bessemer Venture Partners, California Health Care Foundation, CapitalG, CVS Health, Elad Gil, Esther Dyson, Individuals, Institutional Venture Partners, Kaiser Permanente Ventures, KdT Ventures, Khosla Ventures, K. Ventures, Lifepoint Health, Lightspeed Venture Partners, Mass General Brigham (Artificial Intelligence and Digital Innovation Fund), Mayo Clinic, NVentures, Pillar Companies, Redpoint Ventures, SCAN Group, Spark Capital, SV Angel, UC Investments (UCOP), Union Square Ventures, UPMC Enterprises, Whistler Capital Partners, Wittington Ventures, Yoshua Bengio.
As of May 31, 2026, Abridge is not yet publicly traded.
Private companies
OpenAIOPEA+0.28%
SpaceXSPAC+153.37%
StripeSTRI+37.93%
DatabricksDABR+13.60%
AnthropicANTH+234.05%
PerplexityPERP-0.07%
NeuralinkNEUL+186.66%
AndurilADUI+20.64%
Abridge Valuation
Follow estimated valuations, share price trends, and company updates for Abridge.
Private companies
OpenAIOPEA+0.28%
SpaceXSPAC+153.37%
StripeSTRI+37.93%
DatabricksDABR+13.60%
AnthropicANTH+234.05%
PerplexityPERP-0.07%
NeuralinkNEUL+186.66%
AndurilADUI+20.64%